Xcout Intel
IconOVir Bio, Inc. competitors & alternatives
The 12 closest competitors and alternatives to IconOVir Bio, Inc. among biotechnology companies — ranked by similarity to what IconOVir Bio, Inc. actually does, not by market-cap band.
Subscribe to see IconOVir Bio, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About IconOVir Bio, Inc.
IconOVir Bio, Inc. is a preclinical-stage biotechnology company headquartered in New York, United States, with a primary location in San Diego, California. Established in 2020, the venture-backed company is dedicated to pioneering novel oncolytic viral therapies to cure cancer and restore life to patients.
IconOVir Bio, Inc. at a glance
IconOVir Bio, Inc. is a biotechnology company headquartered in United States. It has raised at least $97.2M across the 2 funding rounds on record. Its most recent funding round raised $20.2M in June 2023.
IconOVir Bio, Inc. funding rounds
At least $97.2M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $20.2M | — | |
| Series A | $77M | 8 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 IconOVir Bio, Inc. competitors
Ranked by semantic similarity — how close each company is to IconOVir Bio, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously administered therapeutic. The company focuses on unleashing the power of the immune system and operates as a public company with a small team based in San Diego, California.
Similar biotechnology company
OverT Bio, Inc. is a New York-based biotechnology company that pioneers next-generation cellular therapies and biologics at scale. The company focuses on developing effective and safe cellular treatments for solid tumors.
Similar biotechnology company
CVBio is a biotechnology company that develops virus-driven immunotherapies, specifically utilizing engineered oncolytic adenoviruses to target and destroy resistant cancer cells. The company's platform is designed to treat aggressive cancers, including adult and pediatric brain tumors, by selectively infecting tumor cells and eliciting an anti-tumor immune response.
Similar biotechnology company
Bakx Therapeutics, Inc. is a private biotechnology company founded in 2020 and based in New York, United States. The company specializes in pre-clinical oncology drug pipelines and novel therapeutics discovery.
Biotech
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
Biotech
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Biotech
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Similar biotechnology company
Treovir is a clinical-stage biotechnology company that develops therapies for pediatric brain tumors. Its lead product candidate, G207, is an oncolytic virus therapy currently undergoing clinical trials to treat conditions such as pediatric recurrent glioblastoma.
Similar biotechnology company
Western Oncolytics Ltd. is a cutting-edge biotechnology and pharmaceutical company headquartered in Pittsburgh, Pennsylvania, focused on developing novel cancer therapies and drug pipelines.
Similar biotechnology company
Irazu Oncology, LLC is a biotechnology company that develops cancer immunotherapies utilizing bacterial outer membrane vesicles. The company creates off-the-shelf treatments designed to activate anti-tumor immune responses through a scalable manufacturing process, aiming to provide more accessible and affordable therapeutic options for cancer patients.
Similar biotechnology company
Novita Pharmaceuticals, Inc. is a privately held biopharmaceutical company headquartered in New York, New York, dedicated to developing first-in-class drugs to prevent and treat cancer.
Similar biotechnology company
ImaginAb, Inc. is a global biotechnology company headquartered in California, with operations in Los Angeles and San Diego. It focuses on developing next-generation imaging and radiopharmaceutical products for cancer immunology.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of IconOVir Bio, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for IconOVir Bio, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →